Sat.Oct 14, 2023 - Fri.Oct 20, 2023

article thumbnail

With COVID sales in free-fall, Pfizer slashes revenue forecast by $9B and preps for major cost cuts

Fierce Pharma

As the coronavirus outbreak has shifted to the endemic phase, drugmakers have warned of a drop in demand for COVID-19 products, with the impact coming into focus during the fall vaccination season. | Pfizer has slashed its 2023 revenue projection by $9 billion because of declining demand for COVID products. The company now expects sales to reach between $58 billion and $61 billion, down from a prior range of $67 billion to $70 billion.

Sales 363
article thumbnail

Hyloris wins painkiller approval amidst amplified anti-opioid efforts

Pharmaceutical Technology

The FDA approved Hyloris’s non-opioid painkiller as the agency increases efforts to mitigate an opioid crisis.

FDA 145
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Actor and epilepsy advocate Greg Grunberg wants the world to ‘talk about it’

PharmaVoice

The actor of “Heroes” and “Star Wars: The Force Awakens” fame is starring in another role as a patient advocate for people with epilepsy.

Patients 138
article thumbnail

FDA Forms New Digital Health Advisory Committee to Cover Growing Role of Tech

MedCity News

The FDA’s digital health advisory committee will discuss technologies such as artificial intelligence and machine learning, virtual reality, and digital therapeutics as well as topics like decentralized clinical trials and patient-generated health data. Committee member nominations are due in December.

FDA 136
article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

Merck’s Keytruda wins coveted FDA nod around surgery for early lung cancer—with a surprise

Fierce Pharma

Up until this point, immune checkpoint inhibitors have been allowed to treat early-stage non-small cell lung cancer (NSCLC) either before or after surgery. | Thanks to a new FDA approval for Merck's Keytruda, a continuous immunotherapy regimen around surgery is now available for patients with early-stage non-small cell lung cancer. The drug's label already includes an overall survival win from a key trial.

FDA 354
article thumbnail

Win Your Medical Device Sales interview

David Bagga

The final step of the interview process is usually meeting with a regional sales director or VP of sales, companies will determine who you need to meet with during a final interview. Medical Device Sales Career Home Blog Win Your Medical Device Sales Job… Win Your Medical Device Sales Job The Final Interview The Final […] The post Win Your Medical Device Sales interview appeared first on.

Sales 130

More Trending

article thumbnail

Helping Doctors Help Patients: Digital Health’s Role in Reinventing How the Work That is Healthcare is Delivered

MedCity News

Investing in Friction-reducing tactics such as community building and providing benefits, training, and personalized support to employees will yield compounding long-term benefits while reducing churn rate.

Doctors 135
article thumbnail

ESMO: J&J's Rybrevant combo beats Tagrisso on lung cancer progression. Should AZ worry?

Fierce Pharma

Editor's note: This is an evolving story. Please check back on Oct. 23 when the full data of MARIPOSA are presented at ESMO 2023. | A drug combination from Johnson & Johnson outperformed AstraZeneca’s Tagrisso in slowing the worsening of newly diagnosed lung cancer. But it’ll take more than a tumor progression win to dethrone the EGFR king.

331
331
article thumbnail

Has the science of anti-aging caught up with the dream of a longer life?

PharmaVoice

Billionaire investors and a new crop of longevity biotechs are betting big money on a lifespan-altering tipping point.

122
122
article thumbnail

Pfizer launches cost-cutting drive as COVID sales fall

pharmaphorum

Pfizer launches cost-cutting drive as COVID sales fall Phil.

Sales 122
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

How Mayo Clinic Is Approaching Generative AI Risk Mitigation

MedCity News

At HLTH, Mayo Clinic Platform President John Halamka gave a window into how his health system is mitigating generative AI risks. Some of the measures Mayo is taking include running analyses on how well algorithms perform across various subgroups and training models only on internal de-identified data.

Training 132
article thumbnail

ESMO: Seagen, Astellas and Merck knock it out of the park with Padcev-Keytruda combo in bladder cancer

Fierce Pharma

Editor's Note: Please check back on Oct. 22 when the full data of EV-302 are presented at ESMO 2023. | The results are in for a phase 3 bladder cancer trial assessing the combination of Seagen and Astellas' Padcev, plus Merck's Keytruda, versus standard of care chemotherapy. The figures indicate that the combo can be transformative in the indication.

325
325
article thumbnail

First-in-class phosphate absorption inhibitor approved by FDA

European Pharmaceutical Review

The US Food and Drug Administration (FDA) has approved XPHOZAH ® (tenapanor), the first and only phosphate absorption inhibitor. Ardelyx’s first-in-class oral treatment is indicated to reduce serum phosphorus in adults with chronic kidney disease ( CKD ) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant to phosphate binder therapy.

article thumbnail

Bayer adds QR code to pack to help blind patients

pharmaphorum

Bayer adds QR code to pack to help blind patients Phil.

Patients 122
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

11 HLTH Announcements You Don’t Want to Miss

MedCity News

This year’s HLTH conference brought a bevy of news announcements — from partnerships to new product features to acquisitions and more. In this list, MedCity News compiled short summaries for 11 of the conference’s most notable announcements.

131
131
article thumbnail

Pfizer settles gender pay discrimination allegations at NYC headquarters

Fierce Pharma

Pfizer will cough up $2 million to settle allegations from the U.S. Department of Labor that it underpaid certain women who were employed at the company’s New York City headquarters. | The accusations centered on the company's compensation of 86 female employees in 2015 and 2016. Under the settlement with the Department of Labor, the company must also set aside $500,000 for potential future salary adjustments.

317
317
article thumbnail

The FDA might yank cold medicines from shelves — and that could be just the beginning

PharmaVoice

Phenylephrine’s future is up in the air with an FDA committee saying it’s not effective and a class action lawsuit alleging false advertising. What comes next could have big repercussions.

FDA 119
article thumbnail

Seagen wins future royalties in Enhertu patent dispute

pharmaphorum

Seagen wins future royalties in Enhertu patent dispute Phil.

119
119
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

In Same Day, UCB Lands Two FDA Drug Approvals in Autoimmune Diseases

MedCity News

FDA approval of UCB’s Bimzelx gives the Belgian drugmaker a contender in the crowded plaque psoriasis therapies market. In the rare disease generalized myasthenia gravis, the agency approved Zilbrysq, a UCB drug with advantages over two blockbuster AstraZeneca drugs addressing the same target.

FDA 126
article thumbnail

After long fight, Ardelyx finally bags FDA approval for chronic kidney disease med Xphozah

Fierce Pharma

The third time’s the charm for Ardelyx and its chronic kidney disease med Xphozah (tenapanor). | After the FDA requested more data in 2021, Ardelyx instead defended its drug's profile through two appeals and an advisory committee meeting. Now, the company can celebrate a long-awaited win.

FDA 316
article thumbnail

Parkinson’s UK grants £400,000 to research projects in Scotland

PharmaTimes

The two projects will investigate the potential causes of Parkinson’s disease - News - PharmaTimes

117
117
article thumbnail

VR-based navigation test may detect Alzheimer’s

pharmaphorum

VR-based navigation test may detect Alzheimer’s Phil.

118
118
article thumbnail

How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

article thumbnail

Exo Is On a Mission to Put an Ultrasound Machine In Every Care Provider’s Pocket

MedCity News

With its new handheld ultrasound device, Exo is seeking to take point-of-care ultrasound beyond just the emergency medicine field — into areas like urgent care, primary care and the home. Kurt Hammond, Exo’s chief commercial officer, said that the device sets itself apart from other handheld ultrasound devices, such as those sold by GE, Philips and Butterfly Network, because its AI does a better job of making the ultrasound process quick and easy for providers.

article thumbnail

UCB's approval spree rolls on with FDA nod for Zilbrysq, its 2nd drug for myasthenia gravis

Fierce Pharma

UCB is on an approval roll. | UCB is on an approval roll. Within hours of each other, the Brussels-based company has scored FDA green lights for plaque psoriasis treatment Bimzelx and for generalized myasthenia gravis (gMG) drug Zilbrysq. Not only that, the Zilbrysq endorsement is UCB’s second in the indication this year, coming on top of the FDA signing off on UCB’s Rystiggo in June.

FDA 305
article thumbnail

New £30m initiative launched to support innovation against antimicrobial resistance

PharmaTimes

Global innovators can apply to PACE to receive up to £1m per project - News - PharmaTimes

116
116
article thumbnail

Evident Vascular raises $35m, and other digital financings

pharmaphorum

Evident Vascular raises $35m, and other digital financings Phil.

118
118
article thumbnail

How to Stay Competitive in the Evolving State of Martech

Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr

article thumbnail

Microsoft’s Healthcare AI Efforts Holds Huge Promise for Patients

MedCity News

Microsoft rolled out several AI tools at the HLTH conference last week to enable providers to harness the power of data to be more efficient in their care delivery efforts. The overarching goal is to reduce costs, burnout and improve outcomes. Called Microsoft Fabric, which was rolled out broadly in May, the announcement on October 10 marks the availability of Fabric’s capabilities specifically for the healthcare vertical – to clinicians, administrators but perhaps, most importantly,

article thumbnail

ESMO: In PD-1 battle GSK waged on Merck, Jemperli appears to show survival edge over Keytruda in lung cancer

Fierce Pharma

Last year, a first-of-its-kind head-to-head clinical trial between two PD-1 inhibitors went in GSK’s favor. Now, the British pharma has some new patient survival data to celebrate. | Last year, a first-of-its-kind head-to-head clinical trial between two PD-1 inhibitors went in GSK’s favor. Now, the British pharma has some new patient survival data to celebrate.

Pharma 303
article thumbnail

Digital Learning Programs Webinar

Impetus Digital

Register for one of Impetus’ upcoming webinars between November 20-24: Digital Learning Programs with a Twist About the webinar Last year, we hosted a series of webinars on virtual learning programs. By popular demand, we are bringing them back in November, featuring all the new best practices, tips, and tricks that we’ve picked up in the last 12 months.

Education 116
article thumbnail

Starvation stress key in Micrococcus luteus cleanroom survival

European Pharmaceutical Review

A paper by Tim Sandle, Head of Microbiology, Risk Management and Sterility Assurance at Bio Products Laboratory Ltd has underlined the importance of proper cleanroom disinfection practices by elucidating on the robust survival mechanism of the bacterium Micrococcus luteus (M. luteus). As “one of the most abundant organisms on the outer layer of human skin” M. luteus is a common contaminant recovered from cleanrooms, according to Sandle.

article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time